Downregulation of sulfotransferase expression and activity in diseased human livers

Drug Metabolism and Disposition

Volumn 41, Issue 9, 2013, Pages 1642-1650

  Yalcin, Emine B ^a   More, Vijay ^a   Neira, Karissa L ^a   Lu, Zhenqiang James ^b   Cherrington, Nathan J ^b   Slitt, Angela L ^a   King, Roberta S ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1E1; SULFOTRANSFERASE 2A1; UNCLASSIFIED DRUG;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC CIRRHOSIS; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; FATTY LIVER; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; DOWN-REGULATION; FEMALE; HUMANS; ISOENZYMES; LIVER DISEASES; MALE; MIDDLE AGED; SULFOTRANSFERASES;

EID: 84882755645     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.050930     Document Type: Article

References (60)

1. Akhondi-Meybodi M, Mortazavy-Zadah MR, Hashemian Z, and Moaiedi M (2011) Incidence and risk factors for non-Alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab J Gastroenterol 12:34-36 DOI:10.1016/j.ajg.2011.01.003.
2. Becker U, Gluud C, Farholt S, Bennett P, Micic S, Svenstrup B, and Hardt F (1991) Menopausal age and sex hormones in postmenopausal women with alcoholic and non-Alcoholic liver disease. J Hepatol 13:25-32.
3. Bryan S, Baregzay B, Spicer D, Singal PK, and Khaper N (2013) Redox-inflammatory synergy in the metabolic syndrome. Can J Physiol Pharmacol 91:22-30 DOI:10.1139/cjpp-2012-0295.
4. Buechler C and Weiss TS (2011) Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab 12:24-34.
5. Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, and Lindor K (2008) Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 47:484-492 DOI:10.1002/hep.22063.
6. Chiang DJ, Pritchard MT, and Nagy LE (2011) Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300:G697-G702 DOI:10.1152/ajpgi.00426.2010.
7. Costa JL, Launay JM, and Kirk KL (1983) Exploration of the role of phenolsulfotransferase in the disposition of serotonin in human platelets: implications for a novel therapeutic strategy against depression. Med Hypotheses 10:231-246.
8. Crabb DW (1999) Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 48:184-188.
9. Dooley TP, Haldeman-Cahill R, Joiner J, and Wilborn TW (2000) Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem Biophys Res Commun 277:236-245.
10. Duanmu Z, Weckle A, Koukouritaki SB, Hines RN, Falany JL, Falany CN, Kocarek TA, and Runge-Morris M (2006) Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre-And postnatal human liver. J Pharmacol Exp Ther 316:1310-1317.
11. Eisenhofer G, Coughtrie MW, and Goldstein DS (1999) Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol Suppl 26:S41-S53.
12. Elekima OT, Mills CO, Ahmad A, Skinner GR, Ramsden DB, Bown J, Young TW, and Elias E (2000) Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases. Liver 20:45-50.
13. Falany CN (1997) Enzymology of human cytosolic sulfotransferases. FASEB J 11:206-216.
14. Falany CN, Krasnykh V, and Falany JL (1995) Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol 52:529-539.
15. Falany JL, Pilloff DE, Leyh TS, and Falany CN (2006) Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos 34:361-368 DOI: 10.1124/dmd.105.006551.
16. Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, and Runge-Morris M (2005) Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferatoractivated receptor alpha transcription factor. Mol Pharmacol 67:1257-1267 DOI:10.1124/ mol.104.005389.
17. Finkel Y, Eklöf AC, Granquist L, Soares-da-Silva P, and Bertorello AM (1994) Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats. Gastroenterology 107:675-679.
18. Ghose R, Omoluabi O, Gandhi A, Shah P, Strohacker K, Carpenter KC, McFarlin B, and Guo T (2011) Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 89:57-64 DOI:10.1016/j.lfs.2011.05.005.
19. Glavin GB (1991) Dopamine and gastroprotection. The brain-gut axis. Dig Dis Sci 36: 1670-1672.
20. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, and Méndez-Sánchez N (2010) Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9:402-409.
21. Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, and Cherrington N (2013) Altered UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 41:554-561 DOI:10.1124/dmd.112.048439.
22. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ (2010) Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301 DOI:10.1124/dmd.110.035006.
23. Hashimoto E and Tokushige K (2011) Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 46 (Suppl 1):63-69 DOI:10.1007/s00535- 010-0311-8.
24. Haskel Y and Hanani M (1994) Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Dig Dis Sci 39:2364-2367.
25. Huang J, Bathena SP, Tong J, Roth M, Hagenbuch B, and Alnouti Y (2010) Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica 40:184-194 DOI:10.3109/ 00498250903514607.
26. Jaiswal AK (2000) Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 29:254-262.
27. Kim MS, Shigenaga J, Moser A, Grunfeld C, and Feingold KR (2004) Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am J Physiol Endocrinol Metab 287:E731-E738 DOI:10.1152/ajpendo.00130.2004.
28. Klaassen CD and Boles JW (1997) Sulfation and sulfotransferases 5: the importance of 39-phosphoadenosine 59-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J 11: 404-418.
29. Koga M, Saito H, Mukai M, Saibara T, and Kasayama S (2011) Serum dehydroepiandrosterone sulphate levels in patients with non-Alcoholic fatty liver disease. Intern Med 50:1657-1661 10.2169/internalmedicine.50.4682.
30. Lattuada G, Ragogna F, and Perseghin G (2011) Why does NAFLD predict type 2 diabetes? Curr Diab Rep 11:167-172 10.1007/s11892-011-0190-2.
31. Lazo M and Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28:339-350 10.1055/s-0028- 1091978.
32. Leevy CM (1962) Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore) 41:249-276.
33. Luu-The V, Bernier F, and Dufort I (1996) Steroid sulfotransferases. J Endocrinol 150 (Suppl): S87-S97.
34. McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, and Deaciuc I (2004) Mechanisms of non-Alcoholic steatohepatitis. Alcohol 34:67-79.
35. Merrell MD and Cherrington NJ (2011) Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43:317-334 10.3109/03602532. 2011.577781.
36. Montalto G, Miceli M, Soresi M, Amodio R, Carroccio A, Cartabellotta A, and Castagnetta L (1997) Sex hormones in patients with liver cirrhosis and hepatocellular carcinoma. Oncol Rep 4:173-176.
37. Moore JB (2010) Non-Alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 69:211-220 10.1017/S0029665110000030.
38. Nakamuta M, Ohashi M, Goto K, Tanabe Y, Hiroshige K, and Nawata H (1994) The reevaluation of sex steroids metabolism in patients with non-Alcoholic liver cirrhosis. Fukuoka Igaku Zasshi 85:187-194.
39. Narasaka T, Moriya T, Endoh M, Suzuki T, Shizawa S, Mizokami Y, Matsuoka T, and Sasano H (2000) 17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver. Endocr J 47:697-705.
40. Negishi M, Pedersen LG, Petrotchenko E, Shevtsov S, Gorokhov A, Kakuta Y, and Pedersen LC (2001) Structure and function of sulfotransferases. Arch Biochem Biophys 390:149-157.
41. Nemoto Y, Toda K, Ono M, Fujikawa-Adachi K, Saibara T, Onishi S, Enzan H, Okada T, and Shizuta Y (2000) Altered expression of fatty acid-metabolizing enzymes in aromatasedeficient mice. J Clin Invest 105:1819-1825.
42. Pascale A, Pais R, and Ratziu V (2010) An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 19:415-423.
43. Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, and Waxman DJ (1996) Peroxisome proliferator-Activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol 50:67-74.
44. Reiter C and Weinshilboum RM (1982) Acetaminophen and phenol: substrates for both a thermostable and a thermolabile form of human platelet phenol sulfotransferase. J Pharmacol Exp Ther 221:43-51.
45. Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab Dispos 37:2255-2261 DOI:10.1124/dmd.109.028399.
46. Schumacher M, Liere P, Akwa Y, Rajkowski K, Griffiths W, Bodin K, Sjövall J, and Baulieu EE (2008) Pregnenolone sulfate in the brain: a controversial neurosteroid. Neurochem Int 52: 522-540 DOI:10.1016/j.neuint.2007. 08.022.
47. Shimada M, Watanabe E, Iida Y, Nagata K, and Yamazoe Y (1999) Alteration of hepatic sulfation by endotoxin. Jpn J Pharmacol 80:371-373.
48. Shimizu I and Ito S (2007) Protection of estrogens against the progression of chronic liver disease. Hepatol Res 37:239-247.
49. Sørensen TI, Orholm M, Bentsen KD, Høybye G, Eghøje K, and Christoffersen P (1984) Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 2:241-244.
50. Starr SP and Raines D (2011) Cirrhosis: diagnosis, management, and prevention. Am Fam Physician 84:1353-1359.
51. Strobel G, Friedmann B, Siebold R, and Bärtsch P (1999) Effect of severe exercise on plasma catecholamines in differently trained athletes. Med Sci Sports Exerc 31:560-565.
52. Suiko M, Sakakibara Y, and Liu MC (2000) Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases. Biochem Biophys Res Commun 267:80-84.
53. Tabrett CA and Coughtrie MW (2003) Phenol sulfotransferase 1A1 activity in human liver: kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem Pharmacol 66:2089-2097.
54. Teli MR, Day CP, Burt AD, Bennett MK, and James OF (1995) Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346:987-990.
55. Teubner W, Meinl W, Florian S, Kretzschmar M, and Glatt H (2007) Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404:207-215.
56. Venkatachalam KV (2003) Human 39-phosphoadenosine 59-phosphosulfate (PAPS) synthase: biochemistry, molecular biology and genetic deficiency. IUBMB Life 55:1-11.
57. Völzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Rosskopf D, and Wallaschofski H (2010) Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 33:45-53 DOI:10.1111/j.1365-2605.2009.00953.x.
58. Yasuda S, Liu MY, Suiko M, Sakakibara Y, and Liu MC (2007) Hydroxylated serotonin and dopamine as substrates and inhibitors for human cytosolic SULT1A3. J Neurochem 103: 2679-2689 DOI:10.1111/j.1471-4159.2007.04948.x.
59. Yeo M, Na YM, Kim DK, Kim YB, Wang HJ, Lee JA, Cheong JY, Lee KJ, Paik YK, and Cho SW (2010) The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. Proteomics 10:266-276 DOI:10.1002/pmic.200900721.
60. Yoneda M, Wada K, Katayama K, Nakajima N, Iwasaki T, Osawa E, Mukasa K, Yamada Y, Blumberg RS, and Sekihara H, et al. (2004) A novel therapy for acute hepatitis utilizing dehydroepiandrosterone in the murine model of hepatitis. Biochem Pharmacol 68:2283-2289.